- Walgreens expanding scope of retail pharmacy experience and services heading into fiscal 2014
- Jim Spencer promoted to president of Kinney Drugs stores
- Facing pharmacy trends for the remainder of the year
- Rite Aid posts third consecutive quarterly profit as company expands Wellness+
- Study: Type 2 diabetes market competition heats up amid disease rate increase
SAN DIEGO — Amylin Pharmaceuticals and Alkermes announced that their Type 2 diabetes treatment now is available by prescription in U.S. pharmacies.
Bydureon (exenatide extended-release for injectable suspension) received approval from the Food and Drug Administration on Jan. 27 as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes.
In line with the official launch, the drug makers said eligible patients will have access to the Bydureon Steady Savings Card to help offset co-pay costs by saving up to $50 per month for up to 24 months. Details about the program can be found here.